Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hemagglutinin protein, H5 subtype, of Influenza A virus is a trimeric glycoprotein spike on the viral envelope that mediates host cell attachment by binding to sialic acid-containing receptors, determining host specificity such as avian versus human cells. It undergoes a pH-triggered conformational change in the endosome, exposing a fusion peptide that drives merger of viral and host membranes, enabling genome release into the cell. The H5 subtype, prominent in highly pathogenic avian influenza like H5N1, features a globular head for receptor binding and a conserved stem for fusion, with mutations potentially enhancing mammalian transmission. This protein's variability across 18 HA subtypes drives antigenic drift and shift, complicating vaccine design and necessitating annual updates. As a key viral antigen, H5 hemagglutinin elicits neutralizing antibodies targeting the head to block binding or the stem for broader protection against fusion. Its role in pandemics, such as potential zoonotic jumps from birds to humans, underscores ongoing surveillance needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin protein, H5 subtype, Influenza A virus (H5).